Q32 Bio

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights to its anti-IL-7Rα biologic, bempikibart, from US-based Amgen (NASDAQ: AMGN). The biologic is currently in middle-stage trials for autoimmune diseases. This move follows Amgen’s acquisition of Horizon Therapeutics earlier this year, which had entered into…